News & Updates
Filter by Specialty:
Abiraterone plus prednisolone, enzalutamide a toss-up in castration-resistant prostate cancer
21 Dec 2023
byJairia Dela Cruz
The combination of abiraterone plus prednisolone appears to have similar efficacy and safety as enzalutamide in the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to a study.
Abiraterone plus prednisolone, enzalutamide a toss-up in castration-resistant prostate cancer
21 Dec 2023Somapacitan safe, effective in children with growth hormone deficiency
21 Dec 2023
byStephen Padilla
Use of somapacitan, a long-acting growth hormone (GH) derivative, for 2 years is efficacious and well tolerated in prepubertal children with GH deficiency (GHD), reports a study.
Somapacitan safe, effective in children with growth hormone deficiency
21 Dec 2023Long-term risankizumab safe, effective in moderate-to-severe plaque psoriasis
20 Dec 2023
byStephen Padilla
Treatment with risankizumab in the long term shows lasting efficacy against moderate-to-severe plaque psoriasis and has good tolerability, according to the LIMMitless study.